Vivimed Labs’ JV gets USFDA’s approval for Albendazole Tablets

12 Dec 2018 Evaluate

Vivimed Labs’ 50:50 Joint Venture (JV) strides vivimed Pte, Singapore has received approval for Albendazole Tablets USP 200mg from the United States Food & Drug Administration (USFDA). This is the second generic approval by USFDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets of Amneal pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately $100 million.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs Share Price

16.75 -0.88 (-4.99%)
01-Jan-2026 14:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.05
Dr. Reddys Lab 1251.65
Cipla 1500.90
Zydus Lifesciences 914.00
Lupin 2102.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×